Cite

HARVARD Citation

    Chan, A. et al. (n.d.). Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply. Lancet oncology. 17 (5), pp. e176-e177. [Online]. 
  
Back to record